How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

S. Peters, M. Reck, E. F. Smit, T. Mok, M. D. Hellmann

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Antibodies that target programmed death 1 (PD-1) or its ligand [programmed death ligand 1 (PD-L1)] have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy and in combination with chemotherapy, other immunotherapies, and antiangiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. While immunotherapy has become a central component of first-line treatment of most patients with advanced NSCLC, important questions remain about how treatment should be managed for individual patients.
Original languageEnglish
Pages (from-to)884-896
JournalAnnals of Oncology
Volume30
Issue number6
DOIs
Publication statusPublished - 2019

Cite this

@article{e866540e94514bf280203ec0c84683c7,
title = "How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer",
abstract = "Antibodies that target programmed death 1 (PD-1) or its ligand [programmed death ligand 1 (PD-L1)] have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy and in combination with chemotherapy, other immunotherapies, and antiangiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. While immunotherapy has become a central component of first-line treatment of most patients with advanced NSCLC, important questions remain about how treatment should be managed for individual patients.",
author = "S. Peters and M. Reck and Smit, {E. F.} and T. Mok and Hellmann, {M. D.}",
year = "2019",
doi = "10.1093/annonc/mdz109",
language = "English",
volume = "30",
pages = "884--896",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. / Peters, S.; Reck, M.; Smit, E. F.; Mok, T.; Hellmann, M. D.

In: Annals of Oncology, Vol. 30, No. 6, 2019, p. 884-896.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

AU - Peters, S.

AU - Reck, M.

AU - Smit, E. F.

AU - Mok, T.

AU - Hellmann, M. D.

PY - 2019

Y1 - 2019

N2 - Antibodies that target programmed death 1 (PD-1) or its ligand [programmed death ligand 1 (PD-L1)] have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy and in combination with chemotherapy, other immunotherapies, and antiangiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. While immunotherapy has become a central component of first-line treatment of most patients with advanced NSCLC, important questions remain about how treatment should be managed for individual patients.

AB - Antibodies that target programmed death 1 (PD-1) or its ligand [programmed death ligand 1 (PD-L1)] have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC) without targetable genetic alterations. In this review, we summarize results from recent clinical trials that have evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies atezolizumab and durvalumab as first-line treatment as monotherapy and in combination with chemotherapy, other immunotherapies, and antiangiogenesis agents. We discuss factors that may influence treatment selection, including patient baseline clinical and demographic characteristics, tumor histology, and biomarkers such as PD-L1 expression and tumor mutation burden. While immunotherapy has become a central component of first-line treatment of most patients with advanced NSCLC, important questions remain about how treatment should be managed for individual patients.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071001925&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30912805

U2 - 10.1093/annonc/mdz109

DO - 10.1093/annonc/mdz109

M3 - Review article

VL - 30

SP - 884

EP - 896

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -